Professor Takashi Nakano, Director of the Research Center for Nuclear Physics at the University of Osaka and CTO of Alpha Fusion Inc., will give a lecture at a seminar hosted by the Kansai Pharmaceutical Industries Association (KPIA).

The seminar, themed “Expectations for Nuclear Medicine Therapy,” will be held on August 24, 2026, at Life Science Hub West in Osaka. The event will bring together researchers and industry professionals from the Kansai region to discuss advances in nuclear medicine therapy.

The title of the presentation is as follows:

The Future of Targeted Alpha Therapy Enabled by Astatine-211: From Research Infrastructure to Drug Discovery, Clinical Development, and Social Implementation
(Original title:アスタチン-211が拓く標的アルファ線治療の未来 ― 研究基盤から創薬・臨床開発・社会実装へ ―）
Takashi Nakano, PhD

News&Events

Professor Takashi Nakano, Director of the Research Center for Nuclear Physics at the University of Osaka and CTO of Alpha Fusion Inc., will give a lecture at a seminar hosted by the Kansai Pharmaceutical Industries Association (KPIA).